title: What can we learn from leukemia as for the process of lineage commitment in hematopoiesis?
abstract: Most contemporary models of hematopoiesis assume lineage fidelity of early progenitor cells. Along with this concept normal hematopoietic cells and the majority of leukemias express exclusively myeloid or lymphoid specific antigens. On the other hand, growing evidence exists challenging the lineage fidelity model. Chronic myeloid leukemia (CML) in the blast crisis may switch to acute lymphoblastic leukemia (ALL) and as a result of the chemotherapy ALL may converse to acute myeloid leukemia (AML). Furthermore, a substantial portion of leukemia cases, named acute mixed-lineage leukemia (AMLL), show simultaneous expression of both myeloid and lymphoid antigens. Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements, correlating with myeloid-lymphoid immunophenotype in AMLL, support the hypothesis of lineage infidelity of early progenitor cells, rather than the aberrant antigen expression. Based on a detailed characterization of AMLL we present a modified model of a "common myeloid/lymphoid progenitor cell". This hypothetical very early hematopoietic progenitor cell shows a transient expression of myeloid and B- or T-lymphoid antigen and may also have rearranged its Ig and/or TCR genes. Subsequently, myeloid or lymphoid markers are downregulated and the hematopoietic cell enters either myeloid, T-lymphoid or B-lymphoid differentiation pathway.
authors.affiliation: Humboldt Universität Berlin, Charite Campus Virchow, Augustenburger Platz 1, 13353 Berlin, Germany.
authors.forename: C A
authors.initials: CA
authors.lastname: Schmidt
authors.forename: G K
authors.initials: GK
authors.lastname: Przybylski
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001752:Blast Crisis / Q000473:pathology; D002454:Cell Differentiation; D019070:Cell Lineage; D015329:Gene Rearrangement, T-Lymphocyte; D006410:Hematopoiesis / Q000502:physiology*; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007938:Leukemia / Q000145:classification / Q000473:pathology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology; D016131:Lymphocyte Subsets / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D022423:Myeloid Cells / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000473:pathology*; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D016692:Receptors, Antigen, T-Cell, gamma-delta